Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)
Status:
Unknown status
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The current recommended antibiotic, Cefazolin, treatment for vascular surgery, provides
coverage only for Methicillin-Sensitive Staphylococcus Aureaus (MSSA), other gram-positive
bacteria, and some gram-negative bacteria which may not be adequate antibiotic treatment at
the time of vascular surgery and result in an increased hospital length of stay, increased
cost of care, and an increased risk of morbidity and mortality as a consequence of surgical
site infections. Thus, the investigators want to compare whether Methicillin-resistant
Staphylococcus Aureaus (MRSA) antibiotic prophylaxis with Cefazolin plus Daptomycin is
superior to Cefazolin plus Vancomycin in the reduction of surgical site infection (SSI)
following open arterial revascularization procedures requiring a groin plus lower extremity
incision. The investigators hypothesis is that Cefazolin plus Daptomycin is superior to
Cefazolin plus Vancomycin in the prevention of SSI for high risk patients undergoing open
groin plus lower extremity procedures.